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Background: T wave oversensing (TWOS) is a major drawback of the subcutaneous implantable cardio-
verter deﬁbrillator (S-ICD). Data on predictors of TWOS in S-ICD recipients are limited.
We sought to investigate predictors of TWOS in a cohort of patients receiving an S-ICD at our
institution.
Methods: S-ICD recipients at our center were identiﬁed retrospectively and stratiﬁed based on the
presence or absence of TWOS. Clinical and electrocardiographic parameters were collected and com-
pared between the 2 groups.
Results: Ninety-two patients underwent an S-ICD implantation at our institution between April 2010 and
January 2015. Six (6.5%) patients had TWOS. These patients were younger (38.1713.7 vs. 52.3716.1
years, p¼0.04) and had higher left ventricle ejection fractions (48.5714.9% vs. 28.4712.2%, po0.01)
than patients without a history of TWOS. Baseline 12-lead electrocardiogram (ECG) parameters were not
different between the 2 groups. Leads I, II, and avF (which mimic the sensing vectors of the S-ICD) were
further inspected to identify ECG characteristics that could predict TWOS. The QRS amplitude in ECG lead
I was signiﬁcantly smaller in the TWOS group than in the non-TWOS group (3.7 vs. 7.4 mV, p¼0.02).
Conclusion: In this study, younger age, higher ejection fraction, and lower QRS amplitude were asso-
ciated with TWOS. These ﬁndings could help identify patients referred for S-ICD at high-risk of TWOS.
& 2016 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The subcutaneous implantable cardioverter deﬁbrillator (S-ICD) is
an emerging alternative to the transvenous ICD (T-ICD) for the pre-
vention of sudden cardiac death. The safety and efﬁcacy of this device
have been shown in multiple studies [1–3]. The rate of inappropriate
shocks, speciﬁcally due to T wave oversensing (TWOS), remains an
Achilles heel of this therapy. The original S-ICD studies reported 13–
15% yearly rates of inappropriate shocks [4,5], with TWOS accounting
for the vast majority of cases (estimated as the cause of 64–85% of all
inappropriate shocks [1,3,4]). The addition of a conditional tachy-
cardia detection zone (2 zones vs. 1 zone programming) signiﬁcantly
decreased the rate of inappropriate shocks due to supraventricular
rhythms and TWOS [6]. In aggregate, increased operator experience
with S-ICD programming and routine use of a conditional zone haveblished by Elsevier B.V. This is an
: þ1 404 686 4826.
mi).resulted in a signiﬁcant decrease in the rate of inappropriate shocks,
which has been reﬂected in newer studies reporting an annual
incidence of 5–7% for inappropriate therapies [2,3]. However, TWOS
remains responsible for the majority of these inappropriate shocks.
Limited data are available on the clinical predictors of inap-
propriate shocks [4,7], and therefore, we sought identify clinical
and electrocardiographic predictors of TWOS in a cohort of
patients undergoing S-ICD implantation at our institution.2. Materials and methods
The Emory University institutional review board approved the
study protocol in 2015 (IRB # 00077019). We retrospectively identiﬁed
all patients who underwent S-ICD implantation (Cameron health-
model number 1010 SQ-RX, with a subcutaneous lead-Cameron
health model 3010) at our institution from April 2010 to January





Age (years) 38.1713.7 52.3716.1 0.04
Gender (male) 6 (100) 51 (59.3) 0.08
New York heart association class 2.071.0 2.370.5 0.30
Left ventricular ejection fraction (%) 48.5714.9 28.4712.2 o0.01
History of atrial ﬁbrillation 1 (16.7) 17 (19.8) 1.00
History of ventricular tachycardia 1 (16.7) 19 (22.1) 1.00
Primary arrhythmia syndrome 2 (33.3) 11 (12.8) 0.20
Hypertrophic cardiomyopathy 1 (16.7) 5 (5.8) 0.34
Coronary artery disease 1 (16.7) 29 (33.7) 0.66
Prior myocardial infarction 1 (16.7) 24 (27.9) 1.00
Prior percutaneous coronary
intervention
1 (16.7) 16 (18.6) 1.00
Prior coronary artery bypass grafting 0 20 (23.3) 0.33
History of appropriate deﬁbrillator shocks 1 (16.7) 3 (3.5) 0.24
Chronic lung disease 0 7 (8.1) 1.00
Diabetes mellitus 0 37 (43.0) 0.08
Obstructive sleep apnea 0 12 (13.9) 1.00
Hypertension 3 (50) 68 (79.1) 0.13
End stage renal disease 1 (16.7) 5 (5.8) 0.34
Secondary prevention deﬁbrillator
indication
3 (50) 19 (22.1) 0.15
ACE-I/ARB 1 (16.7) 50 (58.1) 0.09
Beta blockers 4 (66.7) 77 (89.5) 0.15
Diuretics 1 (16.7) 50 (58.1) 0.09
Amiodarone 1 (16.7) 6 (7.0) 0.39
Statins 3 (50) 42 (48.8) 1.00




Data are presented as the mean7standard deviation or n (%).
ACE-I/ARB¼angiotensin converting enzyme inhibitor/angiotensin receptor blocker;
TWOS¼T wave oversensing.
M.F. El-Chami et al. / Journal of Arrhythmia 32 (2016) 181–185182ascertained by medical record review. Data on post-implant clinical
events and survival were obtained from review of medical records and
device-clinic follow-up. Pre-procedure screening for S-ICD candidacy
was performed using body-surface electrocardiograms (ECGs) as
recommended by the manufacturer; however, the ultimate decision to
implant an S-ICD was at the discretion of the implanting physician.
Patients were programmed with 2 tachy-arrhythmia zones (200 and
220 beats/min). All S-ICD shocks were adjudicated by an electro-
physiologist and classiﬁed as appropriate or inappropriate and further
sub-classiﬁed based on cause (i.e., appropriate therapies for ventricular
tachycardia/ﬁbrillation or inappropriate therapies for TWOS or supra-
ventricular rhythms).
Baseline 12-lead ECGs from immediately prior to S-ICD
implantation were reviewed for all patients. Baseline intervals
(PR, QRS, QT) were obtained from the automated ECG measure-
ments. Leads I, II, and aVF were further used to collect data on QRS
and T wave amplitudes, QRS/T amplitude ratio, presence of T wave
inversion, and QRS/T discordance. Leads I, II, and aVF were chosen
for analysis because they mimic the three sensing vectors of the S-
ICD [8]. In each of the three chosen ECG leads, dominant QRS and T
wave amplitudes were measured using manual calipers, and the
presence of T wave inversion and QRS/T discordance was deter-
mined by visual inspection by an electrophysiologist blinded to
other clinical variables.
Patients were stratiﬁed based on the presence or absence of
TWOS during follow-up. Continuous variables are presented as the
mean7standard deviation, and categorical data are summarized
as frequencies and percentages. Comparisons across groups were
performed using the Student's t-test, Fisher's exact test, or one-
way analysis of variance, as appropriate. For all comparisons, a p
value o0.05 was considered to be statistically signiﬁcant. Ana-
lysis was performed using STATISTICA software (Statsoft, Inc.,
Tulsa, OK).3. Results
3.1. Patient characteristics
Ninety-two patients underwent S-ICD implantation. Baseline
characteristics, stratiﬁed by the presence of TWOS, are presented
in Table 1. During a mean follow-up of 13.1714.3 months,
6 patients (6.5%) had TWOS resulting in inappropriate sho-
cks. Patients experiencing TWOS were signiﬁcantly younger
(38.1713.7 vs. 52.3716.1 years, p¼0.04) and had higher left
ventricle ejection fractions (LVEF) (48.5714.9% vs. 28.4712.2%,
po0.01) than patients without TWOS. There was a trend toward
higher prevalence of male gender in the TWOS group. All
6 patients (100%) with inappropriate shocks due to TWOS were
male compared to only 51 patients (59.3%) male gender in the
group without TWOS (p¼0.08). Other baseline characteristics
were similar between the groups. Approximately half of all S-ICD
implants were programmed in the primary sensing vector at
implant, with the secondary vector used next most commonly. The
S-ICD chooses the optimal vector for sensing based on an auto-
mated algorithm that will select the vector with an optimal R to T
ratio and minimal beat-to-beat variability.
Only 1 patient in the TWOS group also experienced an appro-
priate S-ICD shock. In the group without TWOS, 3 patients
experienced appropriate shocks, and 2 patients experienced
inappropriate shocks for non-TWOS etiologies (1 for supraven-
tricular rhythm and 1 for electromagnetic interference).
Baseline ECG parameters stratiﬁed by the presence of TWOS
are presented in Table 2. There were no signiﬁcant differences
between the groups in baseline ECG intervals. QRS amplitudes in
ECG lead I were signiﬁcantly smaller in the TWOS group (3.7 vs.7.4 mV, p¼0.02). Other markers of QRS and T wave amplitude and
morphology were not signiﬁcantly different between the groups.
Twelve-lead ECGs at the time of TWOS episodes were available
on 3 out of 6 patients with TWOS. No signiﬁcant changes or new
conduction delays were noted on these ECGs. The QRS and T wave
amplitudes in lead I were similar at the time of implantation and
at the time of TWOS. QRS and T wave amplitudes at the time of
TWOS as compared to baseline were similar (5.370.6 vs.
3.771.6 mV for QRS amplitude and 1.370.5 vs.1.170.5 for T
wave amplitude).
3.2. Management of TWOS
Six patients presented with inappropriate shocks due to TWOS:
1. A 34-year-old man with hypertrophic cardiomyopathy (HCM)
and sudden cardiac death risk factors underwent S-ICD implan-
tation for primary prevention. He experienced an initial inap-
propriate shock due to TWOS approximately 3 months after
implantation. The sensing vector was changed from primary to
secondary, and the rate cut-offs for delivery of therapy in both
zones were increased. A week later he presented with another
inappropriate shock for TWOS. An exercise treadmill test (ETT)
was performed with acquisition of a new template during
exercise. He currently has had no further inappropriate thera-
pies in the 10 months following this, with activity limitations
per guidelines for management of HCM.
2. A 23-year-old male collegiate basketball player experienced
cardiac arrest during a game and was rescued with an auto-
mated external deﬁbrillator. He was diagnosed with idiopathic
ventricular ﬁbrillation after extensive testing. Two months after
implantation he experienced an inappropriate shock for TWOS.
Table 2
Electrocardiographic predictors of T wave oversensing.
TWOS Control p
(n¼6) (n¼86)
PR interval (ms) 160.0722.9 168.4728.3 0.52
QT interval (ms) 444.3766.8 409.6740.4 0.06
QTc (ms) 456.8739.9 466.4737.9 0.55
QRS axis (deg) 15.07121.1 16.9749.6 0.94
T wave axis (deg) 60.0737.9 41.6781.1 0.58
QRS duration (m) 102.0714.9 101.7717.8 0.97
ECG lead I
QRS amplitude (mV) 3.771.6 7.473.7 0.02
T wave amplitude (mV) 1.170.5 1.570.7 0.14
QRS/T amplitude 3.571.1 5.372.8 0.12
Presence of T wave inversion 1 (16.7) 27 (31.4) 0.66
QRS/T discordance 4 (66.7) 31 (36.1) 0.20
ECG lead II
QRS amplitude (mV) 7.074.8 7.674.4 0.76
T wave amplitude (mV) 1.870.6 1.870.9 0.96
QRS/T amplitude 4.072.1 4.772.5 0.53
Presence of T wave inversion 0 17 (19.8) 0.59
QRS/T discordance 2 (33.3) 26 (30.3) 1.00
ECG lead aVF
QRS amplitude (mV) 6.375.0 6.374.2 0.96
T wave amplitude (mV) 1.770.5 1.570.8 0.51
QRS/T amplitude 3.772.3 4.873.1 0.38
Presence of T wave inversion 0 14 (16.3) 0.59
QRS/T discordance 1 (16.7) 29 (33.7) 0.66
Data are presented as the mean7standard deviation or n (%).
ms¼milliseconds; deg¼degrees; mV¼millivolts; TWOS¼T wave oversensing;
ECG¼electrocardiogram.
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the sensing vector was changed from primary to secondary for
better discrimination of T waves during activity. He has had no
further inappropriate therapies in the 27 months since then.
3. A 25-year-old man with Long QT syndrome and a history of
aborted cardiac arrest underwent extraction of a T-ICD because
of infection attributed to intravenous drug use. He subsequently
underwent implantation of an S-ICD and presented with an
inappropriate shock for TWOS 1 month later (Fig. 1a, b). An ETT
was performed, and the sensing vector was changed from
secondary to primary. He has had no further inappropriate
therapies in the 10 months since then.
4. A 49-year-old man with ischemic cardiomyopathy underwent
S-ICD implantation for primary prevention. Twenty months
later he presented with an inappropriate shock for TWOS in
the setting of sinus tachycardia during an altercation. The
sensing vector was changed from primary to secondary without
further TWOS in the following 37 months.
5. A 50-year-old man with non-ischemic cardiomyopathy and
end-stage renal disease (ESRD) on dialysis with numerous prior
aborted cardiac arrests had previously undergone extraction of
T-ICD systems in 2008 and 2012 for endovascular infection
attributed to ESRD. Following the second episode of T-ICD
infection, he was implanted with an S-ICD and presented
1 month later with two inappropriate shocks for TWOS. Sensing
was adequate at that time, and an ETT was not felt to be feasible
for clinical reasons. No changes were made to the sensing
vectors. Six months later he experienced an appropriate shock
for sustained ventricular tachycardia, which was adequately
detected and treated. However, due to deterioration in his
overall clinical condition, S-ICD therapies were disabled 2 weeks
later, and the patient passed away soon thereafter.6. A 50-year-old man with hypertensive heart disease (LVEF 40%)
presented with syncope and sustained ventricular tachycardia,
which was easily reproduced with an electrophysiology study
and poorly tolerated. Venograms demonstrated bilateral sub-
clavian stenosis, attributed to a history of ESRD, and so he was
implanted with an S-ICD. One month after implantation he
presented with 5 inappropriate shocks due to TWOS in the
setting of light activity. Despite extensive discussions regar-
ding management options, the patient adamantly refused any
efforts to minimize the risk of inappropriate shocks and insis-
ted on device explant, which was performed during that
hospitalization.4. Discussion
TWOS remains one of the major drawbacks of the S-ICD [9,10].
Despite the use of a discrimination algorithm (2 zones vs. 1 zone)
that reduces the rate of TWOS [6], TWOS is commonly encoun-
tered in patients with an S-ICD. In the largest study to date, TWOS
occurred in 5.1% of patients with an S-ICD followed for around
3 years [2], accounting for 39% of all inappropriate shocks. An
algorithm was developed and tested on stored episodes [11], and
this new algorithm reduced the rate of TWOS by around 40%
without compromising the detection of ventricular arrhythmias.
In this study, we retrospectively reviewed 92 patients who
received an S-ICD at our institution and found that the rate of
TWOS was 6.5%, compatible with other contemporary reports of
TWOS [1–5]. The major predictors of TWOS in our cohort were
younger age, higher LVEF, and low QRS amplitude in ECG lead I.
There was also a trend toward increased likelihood of TWOS in
male patients. It is conceivable that younger patients are more
likely to have channelopathies or HCM as an indication for ICD
therapy. These medical conditions are associated with ST-T chan-
ges that could predispose patients to developing TWOS. In addi-
tion, younger age and normal EF might be associated with a higher
likelihood of being physically active, which would therefore result
in higher sinus rates. The latter in the presence of TWOS and
double counting could lead to inappropriate shocks.
Young age has previously been shown to be a predictor of
inappropriate shocks and TWOS in patients with S-ICDs. Jarman
et al. reported on their experience with patients implanted with
an S-ICD in the United Kingdom [4]. Younger age was a strong
predictor of TWOS. In this study, the mean age of patients with
TWOS was 24 years, while that in patients without TWOS was 39
years. In addition, most of these patients had an inherited
arrhythmia syndrome or HCM, which might explain the higher
rate of TWOS in patients with higher LVEF, as also seen in our
study. In a more recent study looking at predictors of inap-
propriate shocks in S-ICD patients enrolled in the EFFORTLESS
registry [7], patients with HCM or a history of atrial ﬁbrillation had
higher rates of inappropriate shocks, predominantly due to
TWOS (73%).
In our study, none of the traditional ECG parameters (QT and PR
intervals, QRS duration) predicted inappropriate shocks due to
TWOS. However, using the ECG leads (I, II, and aVF) that corre-
spond to the S-ICD sensing vectors (primary, secondary, and
alternate, respectively), we were able to identify one baseline ECG
ﬁnding which was associated with an increased risk of TWOS. In
patients with TWOS, the mean QRS amplitude in lead I was
roughly half the amplitude of that in patients without TWOS (3.7
vs. 7.4 mV, p¼0.02). It is conceivable that low QRS amplitude in
lead I may result in a higher likelihood of TWOS due to an
increased likelihood of detecting T waves when the QRS amplitude
is low. The fact that most patients in this cohort were programmed
with the primary S-ICD sensing vector, which most closely
Fig. 1. (a) EGM at implant and at the day of T wave oversensing (TWOS), (b) implantable cardioverter deﬁbrillator (ICD) shock (lightning arrow) due to TWOS; the latter is
seen throughout the EGM. Under-sensing of several beats and occasional T wave sensing rather than QRS sensing is also seen.
M.F. El-Chami et al. / Journal of Arrhythmia 32 (2016) 181–185184corresponds to ECG lead I, may explain why QRS amplitude in
other leads (II and aVF) was not a signiﬁcant predictor of TWOS in
our study.
The major limitation of this study is the small number of
patients with TWOS. However, to our knowledge, it is the ﬁrst
study to date that has attempted to identify baseline ECG pre-
dictors of TWOS. Despite the small size of our TWOS cohort, we
were also able to validate clinical predictors of TWOS which have
been identiﬁed in other studies.5. Conclusion
Despite improvements in device programming strategies,
patients implanted with an S-ICD remain at risk of inappropriate
therapies due to TWOS. Younger age, higher LVEF, and low QRS
amplitude in lead I were signiﬁcantly associated with a higher risk
of TWOS. If validated in a larger study, these ﬁndings could help
reﬁne the identiﬁcation of patients who are candidates for an S-
ICD but who may be at particularly high risk of TWOS.Funding
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